August 30th, 2024
Paper published: Research on Combination Therapy of BNCT and Immune Checkpoint Inhibitors
The Paper “Overcoming immunotherapy resistance and inducing abscopal effects wi……
BNCT
July 16th, 2024
Specified Clinical Research Contract concluded with Edogawa Hospital
― Providing our drug for Research on FDG-PET-positive shallow tumors ― Stell……
The paper “Efficacy and safety of boron neutron capture therapy for Hypopharyng……
June 24th, 2024
BNCT for Thoracic Malignant Tumor – Submission of Trial Plan Notification for Domestic Clinical Trial Phase I/II
We would like to announce that our company submitted the trial plan notificatio……
June 21st, 2024
Treatment results of unresectable, locally recurrent or locally advanced head and neck cancer published
A paper containing the treatment results of unresectable, locally recurrent or ……
May 9th, 2024
BNCT Project in Hong Kong-Shenzhen – Memorandum of Understanding signing ceremony
Together with China Biotech Services Holdings Limited (CBSH), our partner for t……
April 16th, 2024
Paper published: Clinical trial about Boron Neutron Capture Therapy for recurrent breast cancer
Our company provides Steboronine® for the investigator-initiated specified clin……
The international science journal “Nature” published in its special edition “Ra……
March 4th, 2024
Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer
The results regarding safety and effectiveness of our product Borofalan(10B), u……
January 11th, 2024
Investigator-initiated Phase I BNCT clinical trial for newly diagnosed glioblastoma
We would like to announce that Phase I clinical trial for newly diagnosed gliob……
December 25th, 2023
Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma
Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……
December 13th, 2023
Stella Pharma, Mitsubishi Chemical Group, and the University of Tokyo conclude Joint Research Agreement—Accelerating practical application of polyvinyl alcohol (PVA) for boron neutron capture therapy (BNCT)—
Stella Pharma Corporation , Mitsubishi Chemical Corporation of the Mitsubishi C……
